TiumBio grants 70,000 stock options at KRW 4,530 per share

By Public Technologies
  • TiumBio granted stock options covering 70,000 common shares, issued as new shares, with an exercise price of KRW 4,530.
  • Options vest over 2–4 years, with exercise available from Sept. 30, 2028 to Sept. 29, 2033.
  • Award recipients: Park Eun-kyung received 50,000 options; Scott Kim received 20,000 options.
  • Total outstanding stock options rose to 1,041,988 common shares following the grant.
  • Per-option fair value was set at KRW 3,446.90, based on a binomial model using 83.49% expected volatility.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TiumBio Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260930000245), on September 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.